TOP 5 MOST VIEWED ARTICLES
RECENT COMMENTS
Article type: Editorial
Keywords: survival, quality of life, .
This article has 0 comments
Our responsibility to survivors
According to the media version, an individual who develops cancer embarks on a ‘battle’ – those who win are cured, while those who lose die. This simplistic story overlooks the many whose cancer is brought under control rather than cured, as cancer becomes more like a chronic disease. You do not, after all, fight a battle against heart disease, and the media do not present heart patients in terms of winners and losers. But even if we accept the premise of cancer as a battle, then not all survivors celebrate victory. Some have been dreadfully traumatised, not so much by the cancer as by the cure.
» Kathy Redmond
To read the complete article please click on the pdf icon
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.
ESO reserves the absolute right not to publish comments.
ESO reserves the absolute right not to publish comments.
CancerWorld invites you to visit:
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, GlaxoSmithKline, Merck and Novartis.






